GlassScriptPhysician profile
Laurie Macafee
NPI 1912351107
$1,328.87
in general payments reported to CMS, 2019-2025
18 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,328.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.77 | 2025 | |
| Ucb, INC. | $190.71 | 2025 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $148.43 | 2025 | |
| Lundbeck LLC | $113.06 | 2025 | Rexulti, Vyepti |
| Genentech USA, INC. | $77.06 | 2025 | Ocrevus Zunovo |
| Biogen, INC. | $72.37 | 2025 | Tysabri, Vumerity |
| Takeda Pharmaceuticals U.S.A., INC. | $70.66 | 2025 | Hyqvia |
| Argenx US, INC. | $48.83 | 2025 | Vyvgart Hytrulo |
| Pfizer INC. | $47.82 | 2025 | |
| Lilly USA, LLC | $43.00 | 2025 | Kisunla, Zepbound |
| Neurocrine Biosciences, INC. | $38.44 | 2025 | |
| Jazz Pharmaceuticals INC. | $32.50 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $28.91 | 2025 | Rexulti |
| Janssen Biotech, INC. | $28.15 | 2025 | |
| Axsome Therapeutics, INC. | $26.26 | 2025 | Symbravo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24.74 | 2025 | |
| Neurelis, INC. | $23.37 | 2025 | Valtoco |
| Grifols USA, LLC | $21.79 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurie Macafee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.